Drug Database
Back to search

France· FR:61234861

BIVALIRUDINE ACCORD 250 mg, poudre pour solution à diluer pour solution injectable/pour perfusion

A bivalirudin product containing bivalirudine, registered in France by ACCORD HEALTHCARE FRANCE. The same ATC class is registered in 11 of our 19 countries.

ATC B01AE06

Checked against Base de données publique des médicaments — BDPM (France) on

Informational only — not a medical device.

SOURCE REGISTER · FRBase de données publique des médicament…normalisedBIVALIRUDINE ACCORD 250 mg, poudre po…ATCB01AE06REGISTER NO.FR:61234861PACKS LISTED1CHECKEDSeptember 12, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about bivalirudineAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Bivalirudin is registered in 11 of 19 countries.

Countries holding a registration under ATC B01AE06 (bivalirudin), each read from that country’s own register.

  • This record: France, from Base de données publique des médicaments — BDPM (France)
  • 5 of them publish a price we can compare per daily dose
Search bivalirudin products by name

Bivalirudin · ATC B01AE06

11 / 19 countries

  • Belgiumprice
  • Canada
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Netherlands
  • Polandprice
  • Sweden
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Base de données publique des médicaments — BDPM (France)
Active substance
BIVALIRUDINE
Manufacturer
ACCORD HEALTHCARE FRANCE
Country
France (FR)
ATC code
B01AE06
ATC class
Bivalirudin
Defined daily dose
0.25 g, P
Reimbursed
No
Source register
Base de données publique des médicaments — BDPM (France)
Last checked
September 12, 2026

Packs & prices · 1

  • cip13
    3400955048688
    10 flacon(s) en verre de 10 ml

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

148 interactions on record for bivalirudin.

Graded by severity as the source publishes them — 63 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check bivalirudin against other medicinesHow interaction checks work

Bivalirudin · interactions on record

148 records

  • 63 severe
  • 85 moderate

Most severe, free to view

  • DicoumarolB01AA01severe
  • WarfarinB01AA03severe
  • HeparinB01AB01severe
  • DalteparinB01AB04severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Bivalirudin in 10 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All bivalirudin products

Authorised across Europe · EMA

The same active substance is authorised in 13 EEA countries. Names it is sold under:

  • Austria · Bivalirudin Accord
  • Belgium · Bivalirudin Accord Healthcare, Bivalirudin Hikma
  • Germany · Bivalirudin Accord
  • Denmark · Bivalirudin Reig Jofre
  • Spain · Bivalirudina Hikma, Bivalirudina Sala
  • Finland · Bivalirudin Bioglan
  • United Kingdom (Northern Ireland) · Bivalirudin Accord Healthcare, Bivalirudin Kensington Pharma
  • Italy · Bivalirudina Accord, Bivalirudina Hikma
  • Netherlands · Bivalirudine Accord, Bivalirudine Hikma
  • Poland · Biwalirudyna Accord
  • Portugal · Bivalirudina Accord, Bivalirudina Hikma
  • Sweden · Bivalirudin Reig Jofre
  • Slovenia · Bivalirudin Accord

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/4913cc50-8f1b-443e-90ce-f016d9175149
GET /v1/drugs/4913cc50-8f1b-443e-90ce-f016d9175149?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "cis": "61234861",
  "date_amm": "2018-01-15",
  "type_amm": "Procédure décentralisée",
  "numero_ue": null,
  "substance": "BIVALIRUDINE",
  "atc_source": "fr_atc_restore_2026-09-06",
  "statut_amm": "Autorisation active",
  "statut_bdm": null,
  "forme_pharmaceutique": "poudre pour solution à diluer injectable ou pour perfusion",
  "voies_administration": "intraveineuse",
  "etat_commercialisation": "Commercialisée",
  "surveillance_renforcee": "Non"
}
API referenceMCP serverPlans

See everything about bivalirudin.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console